Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 313-319

  Kang, Yanmeng ^a   Ding, Mingjie ^b   Tian, Guangyan ^b   Guo, Haisheng ^c   Wan, Yunyan ^a   Yao, Zhouhong ^a   Li, Bin ^a   Lin, Dianjie ^a  

^a SHANDONG UNIVERSITY   (China)

^b Jinan Children's Hospital   (China)

^c DONGYING PEOPLE S HOSPITAL   (China)

Author keywords

Cisplatin; Epithelioid; Growth; Malignant pleural mesothelioma; Numb; Overexpression; Sensitivity

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYTOCHROME C; ONCOPROTEIN; PROTEIN NUMB; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME REGULATION; ENZYME RELEASE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYTOCHROMES C; DOWN-REGULATION; FEMALE; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MESOTHELIOMA; MIDDLE AGED; NERVE TISSUE PROTEINS; PROGNOSIS; SIGNAL TRANSDUCTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84878206428     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2429     Document Type: Article

References (44)

1. Peto J, Decarli A, La Vecchia C, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999. (Pubitemid 29046253)
2. Bianchi C and Bianchi T: Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 45: 379-387, 2007. (Pubitemid 47217199)
3. Robinson BWS, Musk AW and Lake RA: Malignant mesothelioma. Lancet 366: 397-408, 2005. (Pubitemid 41073959)
4. Beachy PA, Karhadkar SS and Berman DM: Tissue repair and stem cell renewal in carcinogenesis. Nature 432: 324-331, 2004. (Pubitemid 39551660)
5. Uemura T, Shepherd S, Ackerman L, Jan LY and Jan YN: numb, a gene required in determination of cell fate during sensory organ formation in Drosophila embryos. Cell 58: 349-360, 1989.
6. Rhyu MS, Jan LY and Jan YN: Asymmetric distribution of numb protein during division of the sensory organ precursor cell confers distinct fates to daughter cells. Cell 76: 477-491, 1994. (Pubitemid 24064169)
7. Morrison SJ and Spradling AC: Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132: 598-611, 2008. (Pubitemid 351253690)
8. Rašin MR, Gazula VR, Breunig JJ, et al: Numb and Numbl are required for maintenance of cadherin-based adhesion and polarity of neural progenitors. Nat Neurosci 10: 819-827, 2007. (Pubitemid 47013439)
9. Nishimura T and Kaibuchi K: Numb controls integrin endocytosis for directional cell migration with aPKC and PAR-3. Dev Cell 13: 15-28, 2007. (Pubitemid 46972036)
10. McGill MA and McGlade CJ: Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 278: 23196-23203, 2003. (Pubitemid 36830386)
11. Di Marcotullio L, Ferretti E, Greco A, et al: Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat Cell Biol 8: 1415-1423, 2006. (Pubitemid 44835117)
12. Colaluca IN, Tosoni D, Nuciforo P, et al: NUMB controls p53 tumour suppressor activity. Nature 451: 76-80, 2008.
13. Pece S, Confalonieri S, Romano PR and Di Fiore PP: NUMB-ing down cancer by more than just a NOTCH. Biochim Biophys Acta 1815: 26-43, 2011.
14. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
15. Thiery JP, Acloque H, Huang RYJ and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
16. Lanzetti L and Di Fiore PP: Endocytosis and cancer: an 'insider' network with dangerous liaisons. Traffic 9: 2011-2021, 2008.
17. Vaccari T and Bilder D: At the crossroads of polarity, proliferation and apoptosis: the use of Drosophila to unravel the multifaceted role of endocytosis in tumor suppression. Mol Oncol 3: 354-365, 2009.
18. Goldstein B and Macara IG: The PAR proteins: fundamental players in animal cell polarization. Dev Cell 13: 609-622, 2007. (Pubitemid 350011991)
19. Aranda V, Nolan ME and Muthuswamy SK: Par complex in cancer: a regulator of normal cell polarity joins the dark side. Oncogene 27: 6878-6887, 2008.
20. Pece S, Serresi M, Santolini E, et al: Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215-221, 2004. (Pubitemid 39435065)
21. Westhoff B, Colaluca IN, D'Ario G, et al: Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA 106: 22293-22298, 2009.
22. Caussinus E and Gonzalez C: Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat Genet 37: 1125-1129, 2005. (Pubitemid 41486667)
23. Bric A, Miething C, Bialucha CU, et al: Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16: 324-335, 2009.
24. Maiorano E, Favia G, Pece S, et al: Prognostic implications of NUMB immunoreactivity in salivary gland carcinomas. Int J Immunopathol Pharmacol 20: 779-789, 2007.
25. Marino S: Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11: 17-22, 2005.
26. Yan B, Omar FM, Das K, et al: Characterization of Numb expression in astrocytomas. Neuropathology 28: 479-484, 2008.
27. Travis W, Brambilla E, Muller-Hermelink H and Harris C (eds): World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
28. Heidebrecht H, Buck F, Endl E, Kruse M, Adam K and Andresen K: Ki-67-Mcm6, a new MoAb specific to Mcm6: comparison of the distribution profile of Mcm6 and Ki-67 antigen. Lab Invest 81: 1163-1165, 2008.
29. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
30. Kleinberg L, Lie AK, Flørenes VA, Nesland JM and Davidson B: Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 38: 986-994, 2007. (Pubitemid 46899149)
31. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V and Burstein DE: Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 18: 1618-1622, 2005. (Pubitemid 41670662)
32. Gordon G, Mani M, Mukhopadhyay L, et al: Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 211: 447-454, 2007. (Pubitemid 46332556)
33. Gordon G, Mani M, Mukhopadhyay L, et al: Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-α in malignant pleural mesothelioma. J Pathol 211: 439-446, 2007. (Pubitemid 46332555)
34. Hmeljak J, Erčulj N, Dolžan V, Kern I and Cör A: BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. J Cancer Res Clin Oncol 137: 1641-1651, 2011.
35. Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
36. Kobayashi K, Hatano M, Otaki M, Ogasawara T and Tokuhisa T: Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci USA 96: 1457-1462, 1999. (Pubitemid 29098472)
37. Kim KW, Mutter RW, Willey CD, et al: Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 67: 1519-1525, 2007. (Pubitemid 46467182)
38. Xia C, Xu Z, Yuan X, et al: Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1: 687-694, 2002.
39. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007. (Pubitemid 46137553)
40. Boulikas T and Vougiouka M: Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 10: 663-682, 2003.
41. Ikuta K, Takemura K, Kihara M, et al: Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Oncol Rep 13: 1229-1234, 2005.
42. Okouoyo S, Herzer K, Ucur E, et al: Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer 108: 580-587, 2003. (Pubitemid 38036659)
43. Yang X, Zheng F, Xing H, et al: Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 130: 423-428, 2004. (Pubitemid 39044346)
44. Mueller T, Voigt W, Simon H, et al: Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 63: 513-521, 2003. (Pubitemid 36152515)